| |
Peter Myler, Ph.D.
Mission
The Myler laboratory is devoted to the discovery
of novel drug and vaccine strategies against
global infectious disease. Our work focuses on
using molecular, genomic and bioinformatic
approaches to study gene expression in protozoan
pathogens and using high-throughput techniques
to elucidate the structure of bacterial and
viral proteins.
Research
As part of an international
collaboration with the Wellcome Trust Sanger
Institute, The Institute for Genome Research
and the Karolinska Institute, we have
recently completed
sequencing the genomes of three
trypanosomatid parasites (Leishmania
major, Trypanosoma cruzi and T.
brucei). These projects (which are a
joint effort with Ken
Stuart) involved establishing a
high-throughput sequencing capacity at SBRI,
as well as a substantial bioinformatics
capability. The bioinformatics group also
played a key role in the Target
Identification section of the
Structural Genomics of Pathogenic Protozoa
project (headed by Wim Hol at the University
of Washington), by identifying genes from
Leishmania, T. cruzi, T. brucei and
Plasmodium falciparum which are suitable
for high-throughput cloning, expression and
crystallization in order to solve their
three-dimensional structure.
The “Tritryp” genome
sequences revealed unusual gene organization
in trypanosomatids: the protein-coding genes
are arranged in long polycistronic gene
clusters, suggesting that these parasites
employ unusual methods of transcription. Our
laboratory seeks to characterize the
components of the RNA polymerase (RNAP) II
transcription complex and to elucidate the
molecular mechanisms involved in RNAPII-mediated
transcription of protein-coding genes in
L. major. This research utilizes
genome-scale approaches such as microarray-based
transcript mapping and chromatin
immunoprecipitation (ChIP-chip), as well as
more traditional molecular approaches such
as electrophoretic mobility shifts assays,
affinity chromatography, and in vitro
transcription.
In another project (in
collaboration with Dan Zilberstein at the
Technion Institute in Israel), we are using
genome-wide approaches, such as mRNA
expression microarrays and tandem mass
spectrometry, to identify changes in gene
expression during differentiation from the
insect form (promastigotes) to the mammalian
form (amastigotes) of L. donovani and to
elucidate the signaling pathways involved in
this process.
We have recently been award a
large contact from NIAID to establish the
Seattle
Structural Genomics Center for Infectious
Disease. The goal of this project, which
involves collaboration with investigators at
deCODE biostructures, the
University of Washington and Battelle
Memorial Institute, is to use
state-of-the-art structural genomics
technologies to create a collection of three
dimensional protein structures from
NIAID Category A-C pathogens and
organisms causing emerging or re-emerging
infectious diseases. The protein
structures will be made available to the
broad scientific community, where they will
serve as a blueprint for structure-based
drug development, as well as facilitating
vaccine development and other basic
research.
Themes
* regulation of gene expression in protozoan parasites
* genomics and bioinformatics
* structural genomics
Accomplishments
* Completed
Tritryp genome sequences, providing the
basis for discovery of new anti-trypanosomatid
drugs
* Elucidated genome-wide transcription map of
L. major and L.
donovani
* Revealed hundreds of proteins that are up- or
down-regulated during the transition
between insect and mammalian stages of L.
donovani
Support for Dr. Myler’s current research is provided by the National Institutes of Health (NIH)
and the US-Israel Binational Science
Foundation.
|
|